Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY) and Immunocore Holdings (IMCR)
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Eli Lilly & Co (LLY) and Immunocore Holdings (IMCR).
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Eli Lilly & Co (LLY)
BMO Capital analyst Evan Seigerman maintained a Buy rating on Eli Lilly & Co yesterday and set a price target of $1300.00. The company’s shares closed last Tuesday at $922.50.
According to TipRanks.com, Seigerman is a 5-star analyst with an average return of
Currently, the analyst consensus on Eli Lilly & Co is a Strong Buy with an average price target of $1247.71, representing a 34.9% upside. In a report issued on March 30, TipRanks – xAI also upgraded the stock to Buy with a $975.00 price target.
See the top stocks recommended by analysts >>
Immunocore Holdings (IMCR)
Mizuho Securities analyst Graig Suvannavejh maintained a Hold rating on Immunocore Holdings today and set a price target of $38.00. The company’s shares closed last Tuesday at $31.69, close to its 52-week low of $27.19.
According to TipRanks.com, Suvannavejh is a 5-star analyst with an average return of
Immunocore Holdings has an analyst consensus of Moderate Buy, with a price target consensus of $62.67.
Read More on LLY:
Disclaimer & DisclosureReport an Issue
- AI Models Split on Eli Lilly (LLY) as Valuation and Technicals Diverge from Fundamentals
- Novo Nordisk Stock (NVO) Is Cheap and Offers a 5% Dividend Yield
- Novo Nordisk (NVO) Partners with OpenAI — Is Eli Lilly the Real Target?
- Morning News Wrap-Up 4/13/26: Today’s Biggest Stock Market Stories!
- Eli Lilly Stock (LLY) Gets Shot in the Arm from New Leukemia Drug
